Medicine Recommendations

For the Treatment of Major Depressive Episodes in Adults

Anxiety (short term use)

Parkinson's disease (but not drug-induced extrapyramidal symptoms)

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Neuropathic pain

Depressive illness

Migraine prophylaxis, Tension Type Headache prophylaxis

 Neuropathic pain (as per LSCMMG Guidelines)

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Parkinson's disease

Bipolar disorder in Adolescents (NICE TA292)

NICE TA 292 - Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Bipolar disorder in Adults

Maintenance treatment of schizophrenia in adult patients

Treatment of Schizophrenia in adults. Treatment of Schizophrenia in people aged 15 to 17 years (NICE TA213)

NICE TA213 - Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Acute Mania

 Acute Migraine

Preventing migraine (NICE TA973)

NICE TA973 - Atogepant for preventing migraine

ADHD

NICE guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management

MHRA Drug Safety Update - Atomoxetine: increases in blood pressure and heart rate

Control of deviant antisocial sexual behaviour

For treating chronic sialorrhoea (NICE TA605)

NICE TA605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea